On Friday, 10x Genomics Inc (NASDAQ: TXG) opened lower -0.60% from the last session, before settling in for the closing price of $14.90. Price fluctuations for TXG have ranged from $12.95 to $51.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 27.69%. Company’s average yearly earnings per share was noted 35.14% at the time writing. With a float of $100.23 million, this company’s outstanding shares have now reached $106.98 million.
The extent of productivity of a business whose workforce counts for 1259 workers is very important to gauge. In terms of profitability, gross margin is 65.89%, operating margin of -28.3%, and the pretax margin is -27.93%.
10x Genomics Inc (TXG) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Health Information Services industry is another important factor to consider. The insider ownership of 10x Genomics Inc is 17.20%, while institutional ownership is 80.43%. The most recent insider transaction that took place on Nov 22 ’24, was worth 91,612. In this transaction Chief Executive Officer of this company sold 6,693 shares at a rate of $13.69, taking the stock ownership to the 872,574 shares. Before that another transaction happened on Nov 22 ’24, when Company’s insider sold 5,807 for $13.69, making the entire transaction worth $79,485. This insider now owns 339,897 shares in total.
10x Genomics Inc (TXG) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 35.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.30% during the next five years compared to -13.04% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Check out the current performance indicators for 10x Genomics Inc (TXG). In the past quarter, the stock posted a quick ratio of 4.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.85. Likewise, its price to free cash flow for the trailing twelve months is 68.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach -1.27 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
The latest stats from [10x Genomics Inc, TXG] show that its last 5-days average volume of 1.95 million was inferior to 2.02 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 40.13%. Additionally, its Average True Range was 1.09.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 15.75%, which indicates a significant decrease from 24.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.93% in the past 14 days, which was lower than the 72.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.99, while its 200-day Moving Average is $19.98. Now, the first resistance to watch is $15.12. This is followed by the second major resistance level at $15.43. The third major resistance level sits at $15.71. If the price goes on to break the first support level at $14.54, it is likely to go to the next support level at $14.26. The third support level lies at $13.95 if the price breaches the second support level.
10x Genomics Inc (NASDAQ: TXG) Key Stats
There are currently 121,054K shares outstanding in the company with a market cap of 1.79 billion. Presently, the company’s annual sales total 618,730 K according to its annual income of -255,100 K. Last quarter, the company’s sales amounted to 151,650 K and its income totaled -35,750 K.
